^
    Back
    Association details:
    Biomarker:PRAME expression
    Cancer:Solid Tumor
    Drug Class:PRAME inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Dokl Biochem Biophys
    Title:

    Monoclonal Antibodies to PRAME Protein Slow the Development of PRAME-Expressing Tumor

    Published date:
    06/29/2021
    Excerpt:
    Two monoclonal antibodies recognizing non-overlapping epitopes of the PRAME protein were injected into immunocompetent mice to study their influence on the growth of subcutaneous tumor nodes....Each of the antibodies showed the ability to suppress tumor growth of a PRAME-expressing tumour, but not a tumor without PRAME.
    DOI:
    10.1134/S1607672921030091